Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
A study by Mass General Brigham found that taking the weight-loss drug semaglutide before bariatric surgery does not lead to better overall weight loss outcomes. The research suggests that ...
On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as ...
Ozempic (semaglutide) is a prescription drug used for certain conditions in people with type 2 diabetes. Ozempic is given as an injection under your skin. Ozempic can be prescribed for adults with ...
In the note that Nomura shared based on the key takeaways from the conversation, Vohra highlighted that he is “positive on the GLP-1 and semaglutide opportunity in India as Cipla prepares to ...
The Post talked to three people taking semaglutide, plus one weight loss doctor, to find out what’s motivating them to stay mum. Jennifer*, a 50-something from New Jersey, has lost 40 lbs.
Drug compounders have sued the FDA to put the weight loss and diabetes drug semaglutide back on an official shortage list, fighting a regulatory decision … ...
Compounders have been permitted to manufacture copycat versions of Novo’s semaglutide and Lilly’s tirzepatide since 2022 when the FDA declared that both were in shortage. In October ...
This legal move, initiated by the Outsourcing Facilities Association and others in a Fort Worth, Texas federal court, argues that the FDA's ruling, which states no existing shortage of the active ...
Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing the FDA for removing the GLP-1 medication from its shortage list.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback